THN391 MAD
Phase 1Small molecule
THN391 MAD is one of 24 small molecule programs targeting Diabetic Macular Edema. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
32 competitors in Diabetic Macular Edema
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Vabysmo
RocheApproved
Beovu
NovartisApproved
Decadron
AAspen Global Incorporated
Approved
Amaryl
SanofiApproved
Aldactone
PfizerApproved
Kenalog
BBassett Healthcare
Approved
Klor-Con
NovartisApproved
Jardiance
Boehringer IngelheimApproved
Intravitreal Ranibizumab
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetic Macular Edema1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for THN391 MAD. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- TTherini Bio Pty Ltd